What Are Liquid Biopsy Biomarkers?
Liquid biopsy biomarkers are tumor-derived signals measured in blood or other body fluids—ctDNA, circulating tumor cells (CTCs), and cfRNA each answer different clinical questions such as MCED screening, MRD detection, or therapy monitoring. Motif maps published liquid-biopsy associations with PMIDs and cross-references to ClinVar and related databases before teams design validation studies.
TL;DR: Liquid Biopsy Biomarkers
- ctDNA, CTCs, and cfRNA each answer different clinical questions (Wan et al., 2017)
- CCGA reported 51.5% overall cancer signal sensitivity at 99.5% specificity in case-control development (Klein et al., 2021)
- PATHFINDER tested MCED feasibility in asymptomatic adults; cancer signal in 1.4% of participants (Schrag et al., 2023)
- Serial ctDNA can track treatment response before imaging in some settings (Dawson et al., 2013)
- Post-surgical MRD assays stratify recurrence risk in colorectal cancer (Tie et al., 2016; Kotani et al., 2023)
- CHIP in cfDNA can mimic tumor signal; interpret variants in age and clinical context (Razavi et al., 2019)
- Motif maps published liquid-biopsy associations with PMIDs before you design validation studies
From the Motif team: Last reviewed June 2026. Liquid-biopsy literature spans MCED screening, MRD, resistance monitoring, and therapy selection with different assays and endpoints. Motif extracts biomarker-disease associations from PubMed, PMC, and Europe PMC with PMIDs and cross-references to ClinVar and related databases. We do not run assays or clinical decision support.
Liquid biopsies analyze tumor-derived material in blood or other body fluids instead of tissue resection. Wan et al. (2017) review how circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and extracellular vesicles each carry different clinical information.1 The useful question is which analyte fits your intended use, not whether blood is always better than tissue.
Alix-Panabières and Pantel (2021) emphasize that pre-analytical variables (collection tube, processing time, storage) affect liquid biopsy results. DOI: 10.1038/s41571-021-00486-5. Protocols that skip these details often fail to replicate published performance.
What Each Analyte Measures
Circulating tumor DNA (ctDNA)
ctDNA fragments reflect somatic alterations from dying tumor cells. Razavi et al. (2019) showed that plasma cell-free DNA variant sources include tumor and non-tumor contributions, which matters for assay design and false-positive interpretation.2
Applications include mutation detection for targeted therapy, serial monitoring during treatment, and post-surgical minimal residual disease (MRD) assessment when papers report validated assays for those contexts. Read our blog on protein biomarkers for circulating protein complements to DNA panels.
CTCs and extracellular vesicles
CTCs are rare intact tumor cells; isolation and analysis are technically demanding. Exosomes and other vesicles carry proteins and nucleic acids that may complement DNA-only panels. Literature claims should be read per analyte and per indication; pooling heterogeneous assays obscures what replicates.
Cell-free RNA and methylation signals
MCED tests often use targeted methylation patterns rather than mutation panels alone (Klein et al., 2021).3 Methylation signal biology differs from amplicon ctDNA sequencing; performance metrics are not interchangeable across analyte classes.
Core idea: Intended use (screening, MRD, monitoring, mutation calling) determines which liquid biopsy analyte and assay architecture fit the clinical question.
Multi-Cancer Early Detection (MCED)
Klein et al. (2021) reported clinical validation of a targeted methylation MCED test in an independent validation set within the CCGA program.3 In CCGA substudies, overall sensitivity for cancer signal detection was 51.5% with 99.5% specificity, with stage-dependent performance.
Schrag et al. (2023) conducted PATHFINDER, a prospective feasibility study of MCED testing in asymptomatic adults. A cancer signal was detected in 1.4% of participants; diagnostic evaluation confirmed cancer in 0.5%.4 PATHFINDER demonstrates workflow feasibility and diagnostic resolution rates, not mortality reduction from screening. Clinical utility for population MCED requires randomized trials with hard outcomes; conflating case-control sensitivity with screening utility is a common misread of the evidence base (Pepe et al., 2001).5
Case-control validation sensitivity does not automatically transfer to population screening positive predictive value. Literature review must tag study design (case-control vs prospective feasibility vs randomized screening) before citing performance numbers in investor or protocol documents.
Treatment Monitoring and Resistance
Dawson et al. (2013) showed that ctDNA levels tracked metastatic breast cancer burden and could change before imaging in their cohort.6 Serial monitoring claims must cite the specific assay, cancer type, and endpoint used in each study.
Stover et al. (2018) associated ctDNA tumor fraction with outcomes in metastatic triple-negative breast cancer.7 Abbosh et al. (2017) tracked early ctDNA dynamics in early-stage NSCLC using TRACERx, linking variant allele frequency trajectories to relapse risk.8 Early detection and treatment monitoring are different intended uses; pooling their metrics obscures what replicates.
At progression, liquid biopsy can capture emergent resistance alterations. Read our blog on genomic biomarkers in cancer therapy for resistance mechanism literature tied to targeted therapies.
Minimal Residual Disease (MRD)
Tie et al. (2016) reported that circulating tumor DNA detected molecular residual disease and predicted recurrence after colorectal cancer resection.9 Tie et al. (2022) randomized stage II colon cancer to ctDNA-guided versus standard adjuvant chemotherapy in the DYNAMIC trial (15% vs 28% chemotherapy use).10
Kotani et al. (2023) linked postsurgical ctDNA positivity to higher recurrence risk (HR 10.0) in the GALAXY arm of CIRCULATE-Japan.11 MRD literature should be read per tumor type, assay panel, limit of detection, and time point after surgery.
Pepe et al. (2001) describe phased evaluation of diagnostic tests from technical feasibility through impact on patient outcomes.5 MRD programs that cite recurrence prediction without utility trials over-interpret prognostic validity as treatment-guidance evidence.
CHIP and False Positives
Not every somatic variant in plasma comes from the tumor under study. Razavi et al. (2019) showed that plasma cfDNA carries contributions from hematopoietic clones and other non-tumor sources.2 Age, prior chemotherapy, and clonal hematopoiesis prevalence affect how you interpret mutation-only panels in screening versus MRD settings.
Literature review should note whether papers filtered CHIP variants, used paired leukocyte sequencing, or applied age-specific interpretation rules. Assay brochures that report specificity without CHIP context may not match your screening population.
Assay Design Choices That Change Performance
Liquid biopsy programs fail when teams copy a published sensitivity number without matching the assay architecture. Key variables include:
- Targeted versus genome-wide: Mutation panels trade breadth for depth; methylation MCED tests use different signal biology than amplicon ctDNA panels.
- Limit of detection (LOD): MRD claims depend on variant allele frequency cutoffs; two papers reporting "ctDNA positive" may use different LODs.
- Pre-analytics: Collection tube, centrifugation delay, and freeze-thaw cycles shift yield (Alix-Panabières & Pantel, 2021).
- Reference standard: Case-control MCED validation differs from prospective screening feasibility (Klein et al., 2021 vs. Schrag et al., 2023).
- Tumor-informed vs fixed panels: MRD assays that require prior tumor sequencing have different logistics than fixed mutation panels.
When scoping literature in Motif, record assay name, analyte, cancer type, stage, LOD, and comparator for each association.
Choosing the Right Analyte for Your Question
| Clinical question | Typical analyte | Evidence to prioritize |
|---|---|---|
| Screen asymptomatic adults | Methylation or multi-analyte MCED | Case-control validation plus prospective feasibility (Klein et al., 2021; Schrag et al., 2023) |
| Guide targeted therapy | ctDNA mutation panel | Concordance with tissue and FDA-labeled intended use |
| Monitor treatment response | Serial ctDNA allele fraction | Longitudinal cohorts with imaging comparators (Dawson et al., 2013) |
| Post-surgical MRD | Tumor-informed or fixed panels | Tumor-type-specific recurrence endpoints (Tie et al., 2016; Tie et al., 2022; Kotani et al., 2023) |
Regulatory and Analytical Context
FDA-cleared or approved plasma tests exist for specific mutations and companion diagnostic uses (for example EGFR in NSCLC). Each approval carries a defined intended use, specimen type, and analyte. Literature review should map which papers use the same platform and cutoff as your planned assay.
FDA-NIH BEST separates analytical validity, clinical validity, and clinical utility (FDA-NIH, 2016).12 Feasibility studies support workflow planning; they rarely satisfy utility claims alone. Read our blog on biomarker discovery and validation for phased evidence requirements.
Scoping Liquid-Biopsy Evidence in Motif
- Ask a focused question (e.g., ctDNA MRD after colorectal resection, or MCED screening feasibility)
- Search PubMed, PMC, and Europe PMC; record screening counts in search provenance
- Extract associations with assay name, cancer type, stage, sensitivity/specificity, and PMIDs
- Separate discovery cohort papers from independent validation studies
- Cross-reference genes and variants to ClinVar and related sources
- Export cited tables for assay validation plans or protocol backgrounds
Failure modes:
- Attributing CCGA case-control sensitivity to PATHFINDER feasibility outcomes
- Pooling studies that used different LOD thresholds or mutation panels
- Citing MCED screening papers as proof of MRD performance
- Treating Motif exports as analytical validation data
- Ignoring CHIP and clonal hematopoiesis literature in screening populations
See cited literature review and biomarker discovery on Motif.
Related Articles
- Liquid biopsy market analysis: commercial and investment context
- Genomic biomarkers in cancer therapy: alteration-drug pairs and resistance
- Personalized medicine biomarker analysis: precision oncology landscape
Frequently Asked Questions
What is a liquid biopsy biomarker?
Liquid biopsy biomarkers are tumor-derived analytes (ctDNA, CTCs, cfRNA, methylation patterns) measurable in blood or other fluids. Each analyte supports different clinical questions: screening, MRD, monitoring, or mutation detection (Wan et al., 2017).
What is the difference between ctDNA and CTCs?
ctDNA is fragmented tumor DNA in plasma used for mutations, MRD, and serial monitoring. CTCs are intact tumor cells rare in blood, used for enumeration and single-cell analysis. Technical requirements and clinical evidence bases differ (Wan et al., 2017; Alix-Panabières & Pantel, 2021).
How accurate are multi-cancer early detection blood tests?
CCGA case-control validation reported 51.5% sensitivity at 99.5% specificity with stage-dependent performance (Klein et al., 2021). PATHFINDER prospective feasibility detected a cancer signal in 1.4% of asymptomatic adults (Schrag et al., 2023). These are different study designs; metrics are not interchangeable.
What is ctDNA MRD testing?
MRD assays detect residual tumor DNA after curative-intent treatment. Positive ctDNA after colorectal resection predicts recurrence in multiple cohorts (Tie et al., 2016; Kotani et al., 2023) and guided adjuvant chemotherapy use in DYNAMIC (Tie et al., 2022). Performance varies by tumor type, assay LOD, and time point.
What is CHIP and why does it matter for liquid biopsy?
Clonal hematopoiesis introduces somatic variants in blood that are not from the tumor, inflating false positives in mutation-based panels. Razavi et al. (2019) quantified non-tumor cfDNA contributions. Screening and MRD protocols must account for age and hematopoietic clone prevalence.
How should teams review liquid biopsy literature before assay development?
Tag each PMID with analyte, assay platform, study design, cancer type, stage, LOD, and intended use. Motif automates extraction and cross-referencing so validation plans do not pool incompatible MCED, MRD, and monitoring studies.
References
- Wan, J.C.M., et al. (2017). Liquid biopsies come of age. Nature Reviews Cancer, 17(4), 223-238. PMID: 28233803
- Razavi, P., et al. (2019). High-intensity sequencing reveals the sources of plasma cfDNA variants. Nature Medicine, 25(12), 1928-1937. PMID: 31792460
- Klein, E.A., et al. (2021). Clinical validation of a targeted methylation-based multi-cancer early detection test. Annals of Oncology, 32(9), 1167-1177. PMID: 34176681
- Schrag, D., et al. (2023). Blood-based tests for multicancer early detection (PATHFINDER). The Lancet, 402(10409), 1251-1260. PMID: 37805216
- Pepe, M.S., et al. (2001). Phases of biomarker development for early detection of cancer. Journal of the National Cancer Institute, 93(14), 1054-1061. PMID: 11459867
- Dawson, S.J., et al. (2013). Analysis of circulating tumor DNA to monitor metastatic breast cancer. New England Journal of Medicine, 368(13), 1199-1209. PMID: 23484797
- Stover, D.G., et al. (2018). Association of cell-free DNA tumor fraction with survival in metastatic TNBC. Journal of Clinical Oncology, 36(6), 543-553. PMID: 29283787
- Abbosh, C., et al. (2017). Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature, 545(7655), 446-451. PMID: 28420412
- Tie, J., et al. (2016). Circulating tumor DNA detects MRD in stage II colon cancer. Sci Transl Med, 8(346), 346ra77. PMID: 27384348
- Tie, J., et al. (2022). ctDNA-guided adjuvant therapy in stage II colon cancer. NEJM, 386(24), 2261-2272. PMID: 35657320
- Kotani, D., et al. (2023). Molecular residual disease and efficacy of adjuvant chemotherapy in CRC. Nat Med, 29(1), 127-134. PMID: 36646802
- FDA-NIH Biomarker Working Group. (2016). BEST Resource. PMID: 27010052
- Alix-Panabières, C., & Pantel, K. (2021). Liquid biopsy: from discovery to clinical application. Nature Reviews Cancer, 21(6), 374-388. DOI: 10.1038/s41571-021-00486-5
